Sangamo Therapeutics Inc. kicked off the trading day on 10/10/19 with a price decrease of -0.86%, equivalent to -$0.07 relative change for the day. Taking a more long-term approach, SGMO had a 52-week range of $6.26 to $14.86. At the time of this article’s publishing, this stock is trading at $8.05 after starting the trading session at $8.16. At the time of writing, this stock’s 50-day Moving Average stands at $10.56, while the 200-day Moving Average of this stock is currently $10.61.
Currently, this company’s share volume is sitting at $1941844, but has maintained average daily volume of $1.23M. This stock has generated an average Year to Date volume of $1.87 million, alongside an average 20-day volume of $1.12 million. This publicly-traded company’s shares outstanding now amounts to $116.89 million, simultaneously with a float of $115.38 million. The organization now has a market capitalization sitting at $940.96 million.
Sangamo Therapeutics Inc.(SGMO) Ownership Data
Now let’s turn our focus to how large-scale investors are behaving with this stock. Sangamo Therapeutics Inc.’s current insider ownership accounts for 0.10%, in contrast to 70.60% institutional ownership. According to the most recent latest insider trade that took place on May 15 this organization’s EVP & Chief Financial Officer exercised an option 5,000 at the rate of 4.55, making the entire transaction hit 22,750 in total value, affecting insider ownership by 30,512. Preceding that transaction, on May 15 Company’s EVP & Chief Financial Officer sold 5,000 at a price of 10.00, making the whole transaction’s value amount to 50,000. This particular insider is now the holder of 25,512 in total.
If we take a glance at the Ownership summary of Sangamo Therapeutics Inc.’s stock, Institutional holders make up 70.60% of its total stock ownership. All together, they are the legal holders of 116.89M shares. If we focus on the top 3 stockholders for this publicly-traded organization, Wellington Management Co. LLP owns 11,039,985 shares, with BlackRock Fund Advisors in 2nd place owning 8,140,032 shares and The Vanguard Group, Inc. in third place with total ownership of 8,097,210 shares.
Sangamo Therapeutics Inc. (SGMO) Earnings and Revenue Data
In the latest quarterly report that this company released, which was put into the public domain on 6/29/2019, the organization reported -$0.26 earnings per share (EPS) for the three-month period, surpassing the consensus estimate (set at -$0.36) by $0.1.
This company achieved a net margin of -136.73 while generating a return on equity of -27.24. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.35 per share during the current fiscal year.
Sangamo Therapeutics Inc.’s EPS decrease for this current 12-month fiscal period is -0.90%, and is forecasted to reach -1.34 in the upcoming year.
Additional Trading Performance Indicators
Now turning our attention to the current performance indicators for Sangamo Therapeutics Inc., this organization’s Quick Ratio in the last reported quarter now stands at 5.60. The company has managed to achieve an average true range (ATR) of 0.46. Alongside those, its Beta score is 2.77.
Another valuable indicator worth considering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 12.38 for this organization. Plus, this company’s price to book ratio for the last three-month fiscal period reported is 2.07, whereas its price to cash per share for the last quarter landed at 3.77.
In the same vein, SGMO’s Diluted EPS (Earnings per Share) trailing twelve months was posted at -0.99, a figure that is expected to reach -0.34 in the next reported quarter, and analysts expect it will be -1.34 at the market close of one year from today’s date.